Toggle menu
Toggle preferences menu
Toggle personal menu
Not logged in
Your IP address will be publicly visible if you make any edits.
Revision as of 15:06, 14 May 2026 by MediaWiki default (talk | contribs) (Assign pharmacological categories from List_of_CNS-active_medicines)
Opioid, Analgesic
Codeine

Experience

👥 No personal reports yet
No clinical reports yet

Log in to add your own experience.

Problems

No problems yet. Be the first to suggest one.

+ Add a problem

Titration strategies

No titration strategies yet. Be the first to suggest one.

+ Add a titration strategy

Effects

No effects listed yet. Be the first to suggest one.

+ Add an effect

Interactions

Pharmacogenomic + mechanism interactions13 edges
FDA Boxed WarningHighest-evidence regulatory action
Phenotype:CYP2D6 ultrarapid metabolizer avoid FDA Boxed 90 / 100
Avoid codeine. Rapid morphine conversion risks severe toxicity (respiratory depression, death documented in nursing infants of UM mothers and UM children post-tonsillectomy). FDA Boxed Warning; CPIC Strong. Crews KR et al, Clin Pharmacol Ther 2021;110(4):888-96 (PMID 33387367). FDA labeling (boxed: Boxed Warning, Warnings and Precautions, Use in Specific Populations, Patient Co)
Phenotype:CYP2D6 poor metabolizer avoid FDA Boxed 85 / 100
Avoid codeine. Inadequate analgesia (cannot generate morphine). Do not default to tramadol (also CYP2D6-dependent). Crews KR et al, Clin Pharmacol Ther 2021;110(4):888-96 (PMID 33387367). CPIC pair-level A (CYP2D6, OPRM1, COMT, and Opioids) [PMID 22205192, 24458010, 33387367] FDA labeling (boxed: Boxed Warning, Warnings and Precautions, Use in Specific Populations, Patient Co)
Pharmacogenomic guideline recommendationsCPIC and Dutch Pharmacogenetics Working Group clinical guidelines
Phenotype:CYP2D6 normal metabolizer monitor CPIC A 70 / 100
CPIC rec 8093869 [Strong]: Use codeine label recommended age- or weight-specific dosing. CPIC pair-level A (CYP2D6, OPRM1, COMT, and Opioids) [PMID 22205192, 24458010, 33387367]
Phenotype:CYP2D6 intermediate metabolizer monitor CPIC A 45 / 100
CPIC rec 8093865 [Moderate]: Use codeine label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider a non-tramadol opioid. CPIC pair-level A (CYP2D6, OPRM1, COMT, and Opioids) [PMID 22205192, 24458010, 33387367]
Phenotype:CYP2D6 normal metabolizer normal dose CPIC A 10 / 100
Use label-recommended dosing. Crews KR et al, Clin Pharmacol Ther 2021;110(4):888-96 (PMID 33387367). CPIC pair-level A (CYP2D6, OPRM1, COMT, and Opioids) [PMID 22205192, 24458010, 33387367]
Pharmacokinetic mechanismSubstrate / metabolism relationships from primary literature
Enzyme:CYP2D6 prodrug activated by Primary 100 / 100
O-demethylation to morphine, the active analgesic (5-15% of an oral codeine dose). Defines analgesic response.
reversible competitive, effect resolves over ~5 inhibitor half-lives
Enzyme:UGT2B7 substrate minor Primary 30 / 100
Glucuronidation to codeine-6-glucuronide; small analgesic contribution.
Enzyme:CYP3A4 substrate minor Primary 25 / 100
N-demethylation to norcodeine; inactive pathway.
Inferred from pharmacokinetic dataMaterialised by the inference engine; provenance shown per row
Quinidine pk lowers via CYP2D6 Inferred 95 / 100
Quinidine inhibits CYP2D6 (inhibitor_strong, intensity 95); Codeine is a prodrug_activated_by of CYP2D6 (intensity 100). Derived: Codeine exposure lowered.
reversible competitive, effect resolves over ~5 inhibitor half-lives
Inferred via Enzyme:CYP2D6 (exposure lowered)
Fluoxetine pk lowers via CYP2D6 Inferred 90 / 100
Fluoxetine inhibits CYP2D6 (inhibitor_strong, intensity 90); Codeine is a prodrug_activated_by of CYP2D6 (intensity 100). Derived: Codeine exposure lowered.
mechanism-based, interaction persists ~4-6 weeks after stopping the inhibitor
Inferred via Enzyme:CYP2D6 (exposure lowered)
Paroxetine pk lowers via CYP2D6 Inferred 90 / 100
Paroxetine inhibits CYP2D6 (inhibitor_strong, intensity 90); Codeine is a prodrug_activated_by of CYP2D6 (intensity 100). Derived: Codeine exposure lowered.
mechanism-based, interaction persists ~4-6 weeks after stopping the inhibitor
Inferred via Enzyme:CYP2D6 (exposure lowered)
Bupropion pk lowers via CYP2D6 Inferred 85 / 100
Bupropion inhibits CYP2D6 (inhibitor_strong, intensity 85); Codeine is a prodrug_activated_by of CYP2D6 (intensity 100). Derived: Codeine exposure lowered.
reversible competitive, effect resolves over ~5 inhibitor half-lives
Inferred via Enzyme:CYP2D6 (exposure lowered)
Mirabegron pk lowers via CYP2D6 Inferred 55 / 100
Mirabegron inhibits CYP2D6 (inhibitor_moderate, intensity 55); Codeine is a prodrug_activated_by of CYP2D6 (intensity 100). Derived: Codeine exposure lowered.
Inferred via Enzyme:CYP2D6 (exposure lowered)

Patient experience

No patient-experience reports yet.

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

Summary
Classes
Opioid, Analgesic
Common uses
Pharmacy
Pharmacology
Purported mechanism
Mu-opioid receptor agonist; prodrug (metabolized to morphine)